ADC Trials CRO
Support for antibody-drug conjugate development that goes beyond standard oncology execution
Worldwide helps sponsors design and run antibody-drug conjugate (ADC) studies from first-in-human through Phase III with support informed by dosing strategy, safety oversight, operational execution, and the decisions that shape downstream success.
Tell us about your study
We’ll connect you with the right oncology clinical
development team.
Your ADC Challenges
Why ADC Programs Need Different Support
ADC programs bring scientific, safety, and operational demands together in ways that can make development more complex than sponsors expect. Development teams must navigate dose optimization and safety risks that are different from other drug modalities, as well as enrollment in a competitive landscape and biomarker decisions that can significantly shape patient and market access. Worldwide helps sponsors manage that complexity with ADC-specific understanding, oncology operational expertise, and support that keeps safety, execution, and long-term development needs in view.
Dosing Strategy Requires More Than Speed
In ADC development, dose optimization is about maximizing the therapeutic window, not simply moving quickly through escalation. Worldwide helps sponsors find the optimal balance between safety and efficacy that supports both near-term study progress and future success.
Safety Signals Can Reshape the Study
Payload-related safety events such as ocular toxicity, interstitial lung disease (ILD), and pneumonitis can require close monitoring, timely review, and protocol adjustments. Worldwide helps sponsors plan for ADC-specific safety risks without losing momentum.
Biomarker Strategy Can Slow Enrollment
When antigen testing is not standard of care, biomarker-defined recruitment can become a practical barrier to startup and enrollment. Worldwide helps sponsors plan for those realities early so site activation and patient access stay better aligned.
Early Decisions Shape What Follows
Choices made in first-in-human and early phase development can affect expansion strategy, scalability, and regulatory positioning. Worldwide helps sponsors make early decisions with downstream development needs in mind.
Partnership & Approach
Early Decisions With the End in Mind
ADC studies require teams to balance urgency with discipline. Worldwide partners with sponsors to bring together ADC scientific understanding and oncology execution, helping teams move quickly while keeping safety, data integrity, and long-term development strategy in view.
Active ADC Trials
Across Phase I-III
In <2 Months on
Recent FIH Studies
Unique Sites
Why Worldwide
What Makes Worldwide the Right ADC Development Fit?
Worldwide brings a wealth of ADC-specific trial experience, leveraging current knowledge of the landscape to optimize a sponsor’s development path.
Built for ADC Complexity
ADCs are not just another oncology modality. Worldwide supports programs with an integrated understanding of antigen, linker, payload, drug-to-antibody ratio, and bystander effect, helping sponsors plan and execute with the nuances of the ADC drug class in mind.
Fast Starts in a Competitive Setting
ADC sponsors often operate in a crowded environment where startup speed matters. Worldwide has supported recent first-in-human ADC studies that reached first patient in (FPI) within two months while maintaining focus on execution quality.
Active Experience Across ADC Programs
In a fast-moving modality, current experience matters. Worldwide supports ADC studies today across all phases and geographies, giving sponsors a partner with recent operational experience rather than historical familiarity alone.
Breadth From FIH Through Phase III
ADC development needs can shift as programs mature. Worldwide supports ADC studies from first-in-human through Phase III, helping sponsors work with a partner that understands both early development pressure and market access demands.
Early Strategy Supports Later Flexibility
In ADC development, early choices can shape expansion options and future positioning. Worldwide helps sponsors make decisions around target patient population, dose, safety, regions, and study design that preserve flexibility as the program moves forward.
Services & Capabilities
Comprehensive Oncology CRO Services
- Protocol Design and Clinical Development Planning
- Regulatory Consulting and Global Submissions
- Global Project Management
- Feasibility Analysis and Site Selection Strategy
- Site Initiation and Study Start-up
- Patient Enrollment
- Dose Escalation, Optimization and Cohort Management
- Site Monitoring and Management
- Data Management
- Clinical Data Analytics and Review
- Clinical Science
- Biostatistics
- Medical Monitoring
- Safety / Pharmacovigilance
- Medical Writing
Dosing Strategy & Study Design
Worldwide helps sponsors plan ADC studies with attention to dose optimization, study design, cohort strategy, protocol flexibility, and execution risks that can shape the trajectory of the program from the beginning.
Safety Oversight for ADC Risks
ADC programs require careful planning around payload-related safety events. Worldwide helps sponsors support safety monitoring and operational coordination in studies where toxicity signals can rapidly influence what comes next.
Site & Patient Strategy
Worldwide helps sponsors plan for site access, patient recruitment, and enrollment realities in ADC studies, including competitive environments where biomarker-defined populations and operational speed can materially affect timelines.
Global ADC Execution
For sponsors running ADC studies across regions, Worldwide helps manage startup, sites, and broader operational complexity from first-in-human through Phase III with oncology-focused support.
What Our Clients Say
“For Worldwide Clinical Trials, all was according to our expectation. We were able to discuss, we were able to see their understanding of the project. They were challenging our decisions. They were making some strategic proposals. At the end of the day, it was the CRO performance that we were expecting.”
Head of Clinical Operations – Late Phase | Biotech Customer
FAQ & Insights
What Sponsors Need to Know
ADCs are a unique drug class that combine targeted antibody delivery with highly potent payloads. This creates added complexity around dose optimization, safety oversight, biomarker-defined recruitment, and study decisions that can affect downstream success. That means sponsors often need support that connects scientific understanding with practical oncology trial execution.
ADC studies can carry distinct safety risks depending on the payload, dose or target. Ocular toxicity and ILD/pneumonitis are two examples that may require specialized monitoring, training, and protocol planning. Sponsors need teams that can respond quickly when safety signals begin to shape the study.
Early ADC dose decisions should be made with future development in mind. Dose optimization and expansion strategy can influence not only near-term study execution, but also later scalability, PI enthusiasm, and broader market access. That is why these decisions benefit from strategic thinking early.
Success often depends on combining a clear scientific rationale with operational execution that reduces delay and site burden. ADC studies may compete for the same sites and biomarker-defined populations, so speed, site relationships, and effective site management all play an important role.
Yes. Worldwide supports ADC development from first-in-human through Phase III, with active experience across studies, sites, patients, and geographies. That breadth helps sponsors work with a partner that understands both early development pressures and registrational program needs.
Oncology Expertise
Looking for Other Oncology Specializations?
See what Worldwide Clinical Trials can do for you.
Your study has unique goals, risks, and decisions ahead. Tell us a little about your needs, and our team will connect you with the right Worldwide experts to discuss how our scientific, medical, and operational support can help move your program forward with confidence.
